Material Incorrect Information in Public Domain
Epalinges, Switzerland, July 26, 2018 – Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling human diseases has learned that there is inaccurate information in the public domain. Mymetics has learned that Mr. Christian Rochet made a public announcement at a biotech forum in Shanghai, China that was held from May 23 to 25, 2018, stating that a company named Hope Mucosal Vaccines SA (Switzerland) was working under a worldwide exclusive license agreement from Mymetics to undertake Phase II clinical trials for virosome-based mucosal vaccines. Mr. Rochet was announced as the CEO of Hope Mucosal Vaccines SA. Mymetics wants to clarify that it has not signed a worldwide exclusive license agreement with Hope Mucosal Vaccines SA nor, for that matter, with any other company for the clinical development of virosome-based mucosal vaccines.